Recent Updates
Recently added Catalysts

Verve Therapeutics, Inc.

VERVFDA catalysts, PDUFA dates & pipeline intelligence
$11.13
▼ -0.01 · -0.09%

Last traded Jul 24, 2025. This price is not current.

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full VERV financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $2.8652W HIGH $11.41
Volume
10.31 M
Value Traded
114.94 M
Short % Float
27.37%
Days to Cover
1.4
+1.09%Week
-0.18%1 Month
+94.58%3 Month
+39.3%6 Month
-62.9%5 Year
-62.9%All Time

Cash Data

Unlock VERV cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
992.16 M
EPS (TTM)
-2.11
P/E Ratio
-
Ent. Value
563.72 M
Total Shares
89.14 M
Float Shares
65.76 M
Insiders
26.23%
Institutions
73.69%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every VERV catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

VERV Catalyst Timeline

Dated clinical, regulatory and corporate events for Verve Therapeutics, Inc.

Unlock the full VERV catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How VERV actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2025-12-31VERVE-201 (ANGPTL3 Program) Phase 1 data readout Phase 1
Unlock 1 more VERV historical catalyst
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Showing 4 of 4 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
VERVE-102 Gene TherapiesNCT07839936AtherosclerosisPhase 2 NOT YET_RECRUITING 175Mar 1, 2030
VERVE-102 Gene TherapiesNCT06164730Heterozygous Familial HypercholesterolemiaPhase 1 RECRUITING 85Oct 1, 2027
VERVE-201 Gene TherapiesNCT06451770HypercholesterolemiaPhase 1 RECRUITING 132Dec 1, 2027
VERVE-101 Small MoleculesCompletedNCT05398029Heterozygous Familial HypercholesterolemiaPhase 1 COMPLETED 13Feb 14, 2025
Unlock the VERV pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every VERV program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every VERV trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock VERV insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Kathiresan SekarDirector, Officer (Chief Executive Officer)Sell -9,822 346,686 held$4.15 04/02/2025
Unlock the full VERV insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in VERV

Fund % of Portfolio Current MV Shares Owned Activity
Casdin Capital, LLC 4.2 % (180 %) 45.99 M 4.10 M 2.5% ( 100.00 K)
Unlock every fund holding VERV
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in VERV
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see VERV ownership
Insider and institutional ownership, quarter by quarter.

VERV Short Interest

Shares sold short, counted twice a month.

27.37%
Short % of Float
of tradable shares sold short
3.6M
Shares Sold Short
-63.3% vs prior count
1.4 Low
Days to Cover
trading days of normal volume to buy every short share back
2.6M
Avg Daily Volume
the average used for days to cover
Unlock VERV short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock VERV option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live VERV option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock VERV options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How VERV ranks across every disease it competes in

Competitive Position is a premium feature
See how VERV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

VERV News

About Verve Therapeutics, Inc.

Founded2021
BIOPHARMAWATCH ELITE PLUS
Trade the next VERV catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime